Rain Oncology IncChange company Symbol lookupSelect an option...RAIN Rain Oncology IncCEIX CONSOL Energy IncWDBG Neuro-Hitech IncGLRY Inspire Faithward Mid Cap Momentum ETFWCC Wesco International IncTNP-F Tsakos Energy Navigation LtdANEB Anebulo Pharmaceuticals IncNCA Nuveen California Municipal Value FundSGOL abrdn Physical Gold Shares ETFGAB-K Gabelli Equity Trust IncGo
Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| March 9, 2023 | Q4 2022 Earnings Release | -$0.70 | -$0.67 to -$0.45 | -$0.68 |
| November 10, 2022 | Q3 2022 Earnings Release | -$0.68 | -$0.73 to -$0.65 | -$0.70 |
| August 4, 2022 | Q2 2022 Earnings Release | -$0.66 | -$0.69 to -$0.60 | -$0.39 |
| May 4, 2022 | Q1 2022 Earnings Release | -$0.66 | -$0.73 to -$0.65 | -$1.93 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.